Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intracerebral hemorrhage is the least treatable form of stroke. We performed this phase 3 trial to confirm a previous study in which recombinant activated factor VII (rFVIIa) reduced growth of the hematoma and improved survival and functional outcomes. METHODS: We randomly assigned 841 patients with intracerebral hemorrhage to receive placebo (268 patients), 20 microg of rFVIIa per kilogram of body weight (276 patients), or 80 microg of rFVIIa per kilogram (297 patients) within 4 hours after the onset of stroke. The primary end point was poor outcome, defined as severe disability or death according to the modified Rankin scale 90 days after the stroke. RESULTS: Treatment with 80 microg of rFVIIa per kilogram resulted in a significant reduction in growth in volume of the hemorrhage. The mean estimated increase in volume of the intracerebral hemorrhage at 24 hours was 26% in the placebo group, as compared with 18% in the group receiving 20 microg of rFVIIa per kilogram (P=0.09) and 11% in the group receiving 80 microg (P<0.001). The growth in volume of intracerebral hemorrhage was reduced by 2.6 ml (95% confidence interval [CI], -0.3 to 5.5; P=0.08) in the group receiving 20 microg of rFVIIa per kilogram and by 3.8 ml (95% CI, 0.9 to 6.7; P=0.009) in the group receiving 80 microg, as compared with the placebo group. Despite this reduction in bleeding, there was no significant difference among the three groups in the proportion of patients with poor clinical outcome (24% in the placebo group, 26% in the group receiving 20 microg of rFVIIa per kilogram, and 29% in the group receiving 80 microg). The overall frequency of thromboembolic serious adverse events was similar in the three groups; however, arterial events were more frequent in the group receiving 80 microg of rFVIIa than in the placebo group (9% vs. 4%, P=0.04). CONCLUSIONS: Hemostatic therapy with rFVIIa reduced growth of the hematoma but did not improve survival or functional outcome after intracerebral hemorrhage. (ClinicalTrials.gov number, NCT00127283 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1965) · PubMed · Cited by 14,925
ASSESSMENT OF COMA AND IMPAIRED CONSCIOUSNESS
Teasdale, G., & Jennett, B. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91639-0 · Cited by 13,215
Functional evaluation : Barthel index
Mahonery, F. I. (1965) · Medical Entomology and Zoology · Cited by 12,762
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Measurements of acute cerebral infarction: a clinical examination scale.
Brott, T., Adams, H. P., Olinger, C. P., Marler, J. R., Barsan, W. G., Biller, J., Spilker, J., Holleran, R., Eberle, R., & Hertzberg, V (1989) · Stroke · doi:10.1161/01.str.20.7.864 · Cited by 5,911
WILSON, J. T. L., PETTIGREW, L. E. L., & TEASDALE, G. M. (1998) · Journal of Neurotrauma · doi:10.1089/neu.1998.15.573 · Cited by 2,386
The ICH Score: A Simple, Reliable Grading Scale for Intracerebral Hemorrhage
Hemphill, J. C., Bonovich, D. C., Besmertis, L., Manley, G. T., & Johnston, S. C. (2001) · Stroke · doi:10.1161/01.str.32.4.891 · Cited by 2,196
Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality.
Broderick, J. P., Brott, T. G., Duldner, J. E., Tomsick, T., & Huster, G. (1993) · Stroke · doi:10.1161/01.str.24.7.987 · Cited by 1,746
Self-citationEarly Hemorrhage Growth in Patients With Intracerebral Hemorrhage
Brott, T., Broderick, J., Kothari, R., Barsan, W., Tomsick, T., Sauerbeck, L., Spilker, J., Duldner, J., & Khoury, J. (1997) · Stroke · doi:10.1161/01.str.28.1.1 · Cited by 1,477
Self-citationHematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage
Davis, S. M., Broderick, J., Hennerici, M., Brun, N. C., Diringer, M. N., Mayer, S. A., Begtrup, K., & Steiner, T. (2006) · Neurology · doi:10.1212/01.wnl.0000208408.98482.99 · Cited by 1,168
Self-citation
Research works printed but not linked: 2
- Zimmerman RD, 2006, AJNR Am J Neuroradiol, 27, 666
- Mahoney FI, 1965, Md State Med J, 14, 61
Cited by
WRITING COMMITTEE MEMBERS*, O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182742cf6 · Cited by 4,725
Hemphill, J. C., Greenberg, S. M., Anderson, C. S., Becker, K., Bendok, B. R., Cushman, M., Fung, G. L., Goldstein, J. N., Macdonald, R. L., Mitchell, P. H., et al. (2015) · Stroke · doi:10.1161/str.0000000000000069 · Cited by 3,994
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Greenberg, S. M., Ziai, W. C., Cordonnier, C., Dowlatshahi, D., Francis, B., Goldstein, J. N., Hemphill, J. C., Johnson, R., Keigher, K. M., Mack, W. J., et al. (2022) · Stroke · doi:10.1161/str.0000000000000407 · Cited by 1,639
Qureshi, A. I., Mendelow, A. D., & Hanley, D. F. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60371-8 · Cited by 1,526
Morgenstern, L. B., Hemphill, J. C., Anderson, C., Becker, K., Broderick, J. P., Connolly, E. S., Greenberg, S. M., Huang, J. N., Macdonald, R. L., Messé, S. R., et al. (2010) · Stroke · doi:10.1161/str.0b013e3181ec611b · Cited by 1,496
Self-citationIntracerebral haemorrhage: mechanisms of injury and therapeutic targets
Keep, R. F., Hua, Y., & Xi, G. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70104-7 · Cited by 1,308
Campbell, B. C. V., & Khatri, P. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31179-x · Cited by 1,116
Hanley, D. F., Thompson, R. E., Rosenblum, M., Yenokyan, G., Lane, K., McBee, N., Mayo, S. W., Bistran-Hall, A. J., Gandhi, D., Mould, W. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30195-3 · Cited by 927
Self-citationManagement of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology
Kozek-Langenecker, S. A., Afshari, A., Albaladejo, P., Santullano, C. A. A., De Robertis, E., Filipescu, D. C., Fries, D., Görlinger, K., Haas, T., Imberger, G., et al. (2013) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32835f4d5b · Cited by 909
Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials
Broderick, J. P., Adeoye, O., & Elm, J. (2017) · Stroke · doi:10.1161/strokeaha.117.017866 · Cited by 807
Self-citationBlood–Brain Barrier Breakdown in Acute and Chronic Cerebrovascular Disease
Yang, Y., & Rosenberg, G. A. (2011) · Stroke · doi:10.1161/strokeaha.110.608257 · Cited by 789
Intracerebral haemorrhage: current approaches to acute management
Cordonnier, C., Demchuk, A., Ziai, W., & Anderson, C. S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31878-6 · Cited by 725
Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions
Magid-Bernstein, J., Girard, R., Polster, S., Srinath, A., Romanos, S., Awad, I. A., & Sansing, L. H. (2022) · Circulation Research · doi:10.1161/circresaha.121.319949 · Cited by 666
Frontera, J. A., Lewin III, J. J., Rabinstein, A. A., Aisiku, I. P., Alexandrov, A. W., Cook, A. M., del Zoppo, G. J., Kumar, M. A., Peerschke, E. I. B., Stiefel, M. F., et al. (2016) · Neurocritical Care · doi:10.1007/s12028-015-0222-x · Cited by 706
“In a study of noncoagulopathic intraparenchymal hemorrhage patients who received rFVIIa, there was a 5 % excess risk of arterial thrombosis compared to controls [113].”
BackgroundSafety of Recombinant Activated Factor VII in Randomized Clinical Trials
Levi, M., Levy, J. H., Andersen, H. F., & Truloff, D. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006221 · Cited by 677
Inflammation in intracerebral hemorrhage: From mechanisms to clinical translation
Zhou, Y., Wang, Y., Wang, J., Anne Stetler, R., & Yang, Q.-W. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.11.003 · Cited by 628
Demchuk, A. M., Dowlatshahi, D., Rodriguez-Luna, D., Molina, C. A., Blas, Y. S., Dzialowski, I., Kobayashi, A., Boulanger, J.-M., Lum, C., Gubitz, G., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70038-8 · Cited by 642
Defining hematoma expansion in intracerebral hemorrhage: Relationship with patient outcomes
Dowlatshahi, D., Demchuk, A. M., Flaherty, M. L., Ali, M., Lyden, P. L., & Smith, E. E. (2011) · Neurology · doi:10.1212/wnl.0b013e3182143317 · Cited by 641
Yaghi, S., Willey, J. Z., Cucchiara, B., Goldstein, J. N., Gonzales, N. R., Khatri, P., Kim, L. J., Mayer, S. A., Sheth, K. N., & Schwamm, L. H. (2017) · Stroke · doi:10.1161/str.0000000000000152 · Cited by 545
Self-citationKuramatsu, J. B., Gerner, S. T., Schellinger, P. D., Glahn, J., Endres, M., Sobesky, J., Flechsenhar, J., Neugebauer, H., Jüttler, E., Grau, A., et al. (2015) · JAMA · doi:10.1001/jama.2015.0846 · Cited by 568
The surgical management of chronic subdural hematoma
Ducruet, A. F., Grobelny, B. T., Zacharia, B. E., Hickman, Z. L., DeRosa, P. L., Anderson, K., Sussman, E., Carpenter, A., & Connolly, E. S. (2012) · Neurosurgical Review · doi:10.1007/s10143-011-0349-y · Cited by 523
“However, the role of rFVIIa remains unclear given the known side-effects of administration coupled with its extremely high cost [51, 56, 57].”
BackgroundSprigg, N., Flaherty, K., Appleton, J. P., Salman, R. A.-S., Bereczki, D., Beridze, M., Christensen, H., Ciccone, A., Collins, R., Czlonkowska, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31033-x · Cited by 480
Complications of intracerebral haemorrhage
Balami, J. S., & Buchan, A. M. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70264-2 · Cited by 444
Neurological Diseases in Relation to the Blood–Brain Barrier
Rosenberg, G. A. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.197 · Cited by 445
“Factor VII, which promotes clotting, reduced growth of the hematoma in the initial trial, which could not be confirmed in a second study (Mayer et al, 2008).”
BackgroundAl-Shahi Salman, R., Frantzias, J., Lee, R. J., Lyden, P. D., Battey, T. W. K., Ayres, A. M., Goldstein, J. N., Mayer, S. A., Steiner, T., Wang, X., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30253-9 · Cited by 424
Self-citationHanley, D. F., Thompson, R. E., Muschelli, J., Rosenblum, M., McBee, N., Lane, K., Bistran-Hall, A. J., Mayo, S. W., Keyl, P., Gandhi, D., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30234-4 · Cited by 392
Steiner, T., Poli, S., Griebe, M., Hüsing, J., Hajda, J., Freiberger, A., Bendszus, M., Bösel, J., Christensen, H., Dohmen, C., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00110-1 · Cited by 379
Self-citationSpontaneous Intracerebral Hemorrhage
Sheth, K. N. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2201449 · Cited by 360
Predicting Hematoma Expansion After Primary Intracerebral Hemorrhage
Brouwers, H. B., Chang, Y., Falcone, G. J., Cai, X., Ayres, A. M., Battey, T. W. K., Vashkevich, A., McNamara, K. A., Valant, V., Schwab, K., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5433 · Cited by 370
Prospective validation of the ICH Score for 12-month functional outcome
Hemphill, J. C., Farrant, M., & Neill, T. A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b8b332 · Cited by 349
Caceres, J. A., & Goldstein, J. N. (2012) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2012.06.003 · Cited by 328
The Role of Tissue Factor and Factor VIIa in Hemostasis
Mackman, N. (2009) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e31819bceb1 · Cited by 335
“Recently, the efficacy and safety of rFVIIa was assessed in patients with acute intracerebral hemorrhage.(44) Unfortunately, despite a reduction in bleeding the low (20 g/kg) and high (80 g/kg) doses of rFVIIa did not improve clinical outcome.”
BackgroundNeuroinflammation after intracerebral hemorrhage
Mracsko, E., & Veltkamp, R. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00388 · Cited by 344
“Current efforts in clinical trials focus on blood pressure control (Anderson et al., 2013), modified surgical approaches or hemostasis in selected patients (Mayer et al., 2008; Morgan et al., 2008; Newell et al., 2011; Ziai et al., 2014).”
BackgroundCerebral Intraparenchymal Hemorrhage: A Review
Gross, B. A., Jankowitz, B. T., & Friedlander, R. M. (2019) · JAMA · doi:10.1001/jama.2019.2413 · Cited by 326
Surgery for spontaneous intracerebral hemorrhage
de Oliveira Manoel, A. L. (2020) · Critical Care · doi:10.1186/s13054-020-2749-2 · Cited by 323
Role and mechanisms of cytokines in the secondary brain injury after intracerebral hemorrhage
Zhu, H., Wang, Z., Yu, J., Yang, X., He, F., Liu, Z., Che, F., Chen, X., Ren, H., Hong, M., et al. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.03.003 · Cited by 318
Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Lin, Y., Stanworth, S., Birchall, J., Doree, C., & Hyde, C. (2007) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005011.pub2 · Cited by 170
Density and Shape as CT Predictors of Intracerebral Hemorrhage Growth
Barras, C. D., Tress, B. M., Christensen, S., MacGregor, L., Collins, M., Desmond, P. M., Skolnick, B. E., Mayer, S. A., Broderick, J. P., Diringer, M. N., et al. (2009) · Stroke · doi:10.1161/strokeaha.108.536888 · Cited by 313
Self-citationLi, Q., Zhang, G., Huang, Y.-J., Dong, M.-X., Lv, F.-J., Wei, X., Chen, J.-J., Zhang, L.-J., Qin, X.-Y., & Xie, P. (2015) · Stroke · doi:10.1161/strokeaha.115.009185 · Cited by 305
Marchesi, C., Pierfranceschi, M., Crowther, M., Garcia, D., Hylek, E., Witt, D., Clark, N., Squizzato, A., Imberti, D., Ageno, W., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-01-0052 · Cited by 306
Li, Q., Zhang, G., Xiong, X., Wang, X.-C., Yang, W.-S., Li, K.-W., Wei, X., & Xie, P. (2016) · Stroke · doi:10.1161/strokeaha.116.013186 · Cited by 286
Hematoma Expansion following Acute Intracerebral Hemorrhage
Brouwers, H. B., & Greenberg, S. M. (2013) · Cerebrovascular Diseases · doi:10.1159/000346599 · Cited by 256
Statistical Analysis of the Primary Outcome in Acute Stroke Trials
Bath, P. M. W., Lees, K. R., Schellinger, P. D., Altman, H., Bland, M., Hogg, C., Howard, G., & Saver, J. L. (2012) · Stroke · doi:10.1161/strokeaha.111.641456 · Cited by 266
Hematoma growth and outcomes in intracerebral hemorrhage: The INTERACT1 study
Delcourt, C., Huang, Y., Arima, H., Chalmers, J., Davis, S. M., Heeley, E. L., Wang, J., Parsons, M. W., Liu, G., Anderson, C. S., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318260cbba · Cited by 261
Self-citationSelim, M., Foster, L. D., Moy, C. S., Xi, G., Hill, M. D., Morgenstern, L. B., Greenberg, S. M., James, M. L., Singh, V., Clark, W. M., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30069-9 · Cited by 252
Anderson, C. S., Huang, Y., Arima, H., Heeley, E., Skulina, C., Parsons, M. W., Peng, B., Li, Q., Su, S., Tao, Q. L., et al. (2010) · Stroke · doi:10.1161/strokeaha.109.561795 · Cited by 257
Management of Intracerebral Hemorrhage
Schrag, M., & Kirshner, H. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.066 · Cited by 243
Delgado Almandoz, J. E., Yoo, A. J., Stone, M. J., Schaefer, P. W., Goldstein, J. N., Rosand, J., Oleinik, A., Lev, M. H., Gonzalez, R. G., & Romero, J. M. (2009) · Stroke · doi:10.1161/strokeaha.109.554667 · Cited by 247
Boulouis, G., Morotti, A., Brouwers, H. B., Charidimou, A., Jessel, M. J., Auriel, E., Pontes-Neto, O., Ayres, A., Vashkevich, A., Schwab, K. M., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.1218 · Cited by 245
Hanley, D. F. (2009) · Stroke · doi:10.1161/strokeaha.108.535419 · Cited by 251
Intracerebral haemorrhage expansion: definitions, predictors, and prevention
Morotti, A., Boulouis, G., Dowlatshahi, D., Li, Q., Shamy, M., Salman, R. A.-S., Rosand, J., Cordonnier, C., Goldstein, J. N., & Charidimou, A. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00338-6 · Cited by 220
Advances in the management of intracerebral hemorrhage
Adeoye, O., & Broderick, J. P. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.146 · Cited by 237
Self-citationYank, V., Tuohy, C. V., Logan, A. C., Bravata, D. M., Staudenmayer, K., Eisenhut, R., Sundaram, V., McMahon, D., Olkin, I., McDonald, K. M., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-8-201104190-00004 · Cited by 240
“…(Reference) rFVIIa Events/Total, n/n Usual Care Events/Total, n/n ICH, low dose Mayer et al, 2005 (30) Mayer et al, 2005 (31) Mayer et al, 2006 (32) Mayer et al, 2008 (33) Combined ICH, medium dose Mayer et al, 2005 (30) Mayer et al, 2005 (31) Mayer et al, 2006 (32) Mayer et al, 2008 (33) Combined…”
Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II: Design, Methods, and Rationale
Qureshi, A. I., & Palesch, Y. Y. (2011) · Neurocritical Care · doi:10.1007/s12028-011-9538-3 · Cited by 229
“A subgroup analysis of the FAST [12] data suggested that if patients selected were age 70 years, with baseline hematoma 60 ml, and baseline IVH volume 5 ml and time to onset B 2.5 h, the OR for poor outcome at 90 days decreased to 0.28 (95% CI 0.08–1.06) with rfVIIa.”
InfluentialIntracerebral hemorrhage outcome: A comprehensive update
Pinho, J., Costa, A. S., Araújo, J. M., Amorim, J. M., & Ferreira, C. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.01.013 · Cited by 222
Tsze, D. S., & Valente, J. H. (2011) · Emergency Medicine International · doi:10.1155/2011/734506 · Cited by 214
“However, adult studies have not demonstrated improved survival or functional outcome at this time [94].”
BackgroundVascular disruption and blood–brain barrier dysfunction in intracerebral hemorrhage
Keep, R. F., Zhou, N., Xiang, J., Andjelkovic, A. V., Hua, Y., & Xi, G. (2014) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-11-18 · Cited by 220
“This may have been related to adverse side effects (particularly systemic) of factor VIIa and the fact that only the 30% of patients that undergo hematoma expansion would be expected to benefit.”
BackgroundHong, K.-S., & Saver, J. L. (2009) · Stroke · doi:10.1161/strokeaha.109.561365 · Cited by 213
Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Simpson, E., Lin, Y., Stanworth, S., Birchall, J., Doree, C., & Hyde, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005011.pub4 · Cited by 183
Naidech, A. M., Jovanovic, B., Liebling, S., Garg, R. K., Bassin, S. L., Bendok, B. R., Bernstein, R. A., Alberts, M. J., & Batjer, H. H. (2009) · Stroke · doi:10.1161/strokeaha.109.550939 · Cited by 213
Morotti, A., Boulouis, G., Dowlatshahi, D., Li, Q., Barras, C. D., Delcourt, C., Yu, Z., Zheng, J., Zhou, Z., Aviv, R. I., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25563 · Cited by 202
The Acute Management of Intracerebral Hemorrhage: A Clinical Review
Elliott, J., & Smith, M. (2010) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181d568c8 · Cited by 202
“However, a subsequent phase III trial in 841 patients, the Factor VII for Acute Hemorrhagic Stroke (FAST) study, failed to replicate these clinical outcomes.(46) In this 2-dose study (rFVIIa 20 and 80 g/kg), the dose-related reduction in hematoma expansion did not translate into a beneficial effect on the risk of deat…”
BackgroundMobile stroke units for prehospital thrombolysis, triage, and beyond: benefits and challenges
Fassbender, K., Grotta, J. C., Walter, S., Grunwald, I. Q., Ragoschke-Schumm, A., & Saver, J. L. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30008-x · Cited by 195
Hypothermia Reduces Perihemorrhagic Edema After Intracerebral Hemorrhage
Kollmar, R., Staykov, D., Dörfler, A., Schellinger, P. D., Schwab, S., & Bardutzky, J. (2010) · Stroke · doi:10.1161/strokeaha.110.587758 · Cited by 199
Brain edema formation and therapy after intracerebral hemorrhage
Wan, Y., Holste, K. G., Hua, Y., Keep, R. F., & Xi, G. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105948 · Cited by 186
Clinical Nihilism in Neuroemergencies
Hemphill, J. C., & White, D. B. (2009) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2008.08.009 · Cited by 196
(2021) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-64034-5.00019-5 · Cited by 158
Delgado Almandoz, J. E., Yoo, A. J., Stone, M. J., Schaefer, P. W., Oleinik, A., Brouwers, H. B., Goldstein, J. N., Rosand, J., Lev, M. H., Gonzalez, R. G., et al. (2010) · Stroke · doi:10.1161/strokeaha.109.565382 · Cited by 189
The critical care management of spontaneous intracranial hemorrhage: a contemporary review
de Oliveira Manoel, A. L., Goffi, A., Zampieri, F. G., Turkel-Parrella, D., Duggal, A., Marotta, T. R., Macdonald, R. L., & Abrahamson, S. (2016) · Critical Care · doi:10.1186/s13054-016-1432-0 · Cited by 175
“FAST trial [153] Multicenter, randomized, double blinded, placebo-controlled trial Eligible patients: spontaneous ICH within 3 hours of symptom onset Exclusion criteria: GCS≤ 5; secondary ICH; known use of anticoagulant therapy, thrombocytopenia, or coagulopathy; acute sepsis; crush injury; disseminated intravascular…”
BackgroundProphylactic Antiepileptic Drug Use is Associated with Poor Outcome Following ICH
for the CHANT investigators, Messé, S. R., Sansing, L. H., Cucchiara, B. L., Herman, S. T., Lyden, P. D., & Kasner, S. E. (2009) · Neurocritical Care · doi:10.1007/s12028-009-9207-y · Cited by 185
“The primary outcome measure was poor outcome at day 90, defined as a modified Rankin scale score of 5 or 6 (severely disabled or dead), which has been used as the primary outcome of interest in recent therapeutic trials for ICH [11].”
MethodSteiner, T., Böhm, M., Dichgans, M., Diener, H.-C., Ell, C., Endres, M., Epple, C., Grond, M., Laufs, U., Nickenig, G., et al. (2013) · Clinical Research in Cardiology · doi:10.1007/s00392-013-0560-7 · Cited by 183
“This complication occurs in about 30 % of patients with spontaneous ICH (SICH) within the first 4 h after onset of symptoms [53].”
BackgroundSelf-citationAbnormal Coagulation Tests Are Associated With Progression of Traumatic Intracranial Hemorrhage
Allard, C. B., Scarpelini, S., Rhind, S. G., Baker, A. J., Shek, P. N., Tien, H., Fernando, M., Tremblay, L., Morrison, L. J., Pinto, R., et al. (2009) · Journal of Trauma: Injury, Infection & Critical Care · doi:10.1097/ta.0b013e3181ad5d37 · Cited by 180
European Stroke Organisation Recommendations to Establish a Stroke Unit and Stroke Center
Ringelstein, E. B., Chamorro, A., Kaste, M., Langhorne, P., Leys, D., Lyrer, P., Thijs, V., Thomassen, L., & Toni, D. (2013) · Stroke · doi:10.1161/strokeaha.112.670430 · Cited by 177
Li, Q., Yakhkind, A., Alexandrov, A. W., Alexandrov, A. V., Anderson, C. S., Dowlatshahi, D., Frontera, J. A., Hemphill, J. C., Ganti, L., Kellner, C., et al. (2024) · Stroke · doi:10.1161/strokeaha.123.043033 · Cited by 167
Self-citationMorgan, T. C., Dawson, J., Spengler, D., Lees, K. R., Aldrich, C., Mishra, N. K., Lane, K., Quinn, T. J., Diener-West, M., Weir, C. J., et al. (2013) · Stroke · doi:10.1161/strokeaha.112.670653 · Cited by 175
Naff, N., Williams, M. A., Keyl, P. M., Tuhrim, S., Bullock, M. R., Mayer, S. A., Coplin, W., Narayan, R., Haines, S., Cruz-Flores, S., et al. (2011) · Stroke · doi:10.1161/strokeaha.110.610949 · Cited by 176
Self-citationModeling Stroke Patient Transport for All Patients With Suspected Large-Vessel Occlusion
Holodinsky, J. K., Williamson, T. S., Demchuk, A. M., Zhao, H., Zhu, L., Francis, M. J., Goyal, M., Hill, M. D., & Kamal, N. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.2424 · Cited by 168
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors
Milling, T. J., Middeldorp, S., Xu, L., Koch, B., Demchuk, A., Eikelboom, J. W., Verhamme, P., Cohen, A. T., Beyer-Westendorf, J., Gibson, C. M., et al. (2023) · Circulation · doi:10.1161/circulationaha.121.057844 · Cited by 164
Mayer, S. A., Davis, S. M., Skolnick, B. E., Brun, N. C., Begtrup, K., Broderick, J. P., Diringer, M. N., & Steiner, T. (2009) · Stroke · doi:10.1161/strokeaha.108.524470 · Cited by 175
Self-citationUpdate in Intracerebral Hemorrhage
Aguilar, M. I., & Brott, T. G. (2011) · The Neurohospitalist · doi:10.1177/1941875211409050 · Cited by 163
“For noncoagulopathic ICH, the use of procoagulant agents like recombinant factor VIIa (rFVIIa) demonstrated efficacy in reducing hematoma growth in a phase II trial(85) but failed to demonstrate clinical improvement over placebo in a subsequent phase III trial.(86) Based on these data, we do not advise rFVIIa use outs…”
MethodOptions to Restrict Hematoma Expansion After Spontaneous Intracerebral Hemorrhage
Steiner, T., & Bösel, J. (2010) · Stroke · doi:10.1161/strokeaha.109.552919 · Cited by 172
Self-citationPredictors of Hematoma Volume in Deep and Lobar Supratentorial Intracerebral Hemorrhage
Falcone, G. J., Biffi, A., Brouwers, H. B., Anderson, C. D., Battey, T. W. K., Ayres, A. M., Vashkevich, A., Schwab, K., Rost, N. S., Goldstein, J. N., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.98 · Cited by 164
Purrucker, J. C., Haas, K., Rizos, T., Khan, S., Wolf, M., Hennerici, M. G., Poli, S., Kleinschnitz, C., Steiner, T., Heuschmann, P. U., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3682 · Cited by 163
Self-citationAcute management of bleeding in patients on novel oral anticoagulants
Siegal, D. M., & Crowther, M. A. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs408 · Cited by 166
“–67 There is concern regarding thrombogenicity in nonhaemophiliac patients.(67,68) In a meta-analysis, arterial thromboembolic events were increased in non-haemophiliac patients treated with rVIIa compared with placebo (4.”
BackgroundChristensen, H., Cordonnier, C., Kõrv, J., Lal, A., Ovesen, C., Purrucker, J. C., Toni, D., & Steiner, T. (2019) · European Stroke Journal · doi:10.1177/2396987319849763 · Cited by 171
“Treatment was associated with increased risk of thromboembolic complications.(26,27) A retrospective observational study compared early reversal using FFP or rFVIIa with late reversal(28) in a total of 56 patients with VKA-ICH.”
Self-citationMultidisciplinary Approach to the Challenge of Hemostasis
Levy, J. H., Dutton, R. P., Hemphill, J. C., Shander, A., Cooper, D. J., Paidas, M. J., Kessler, C. M., Holcomb, J. B., & Lawson, J. H. (2010) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181c84ba5 · Cited by 179
“In the wake of recent experience with aprotinin in cardiac surgery and rFVIIa in acute ICH, measuring only intermediate end points such as reduced blood loss, amount of units transfused, or hematoma expansion is important, but may not be sufficient for future trials of hemostatic agents.(11,44) Clinical studies of ble…”
BackgroundLi, Q., Warren, A. D., Qureshi, A. I., Morotti, A., Falcone, G. J., Sheth, K. N., Shoamanesh, A., Dowlatshahi, D., Viswanathan, A., & Goldstein, J. N. (2020) · Annals of Neurology · doi:10.1002/ana.25793 · Cited by 159
“5 hours.(28,29) A large study of reversal of anticoagulation suggested a benefit of intensive BP reduction, plus rapid anticoagulant reversal, only within the first few hours.”
BackgroundManagement of Intraventricular Hemorrhage
Hinson, H. E., Hanley, D. F., & Ziai, W. (2010) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-010-0086-6 · Cited by 168
Qureshi, A. I., Chaudhry, S., Sapkota, B. L., Rodriguez, G. J., & Suri, M. F. K. (2012) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2012.02.032 · Cited by 163
“Such attributes include: (1) availability of the data at the time of discharge and with no impact of attrition because of loss to follow-up; (2) comprehensible for patients and family to understand; (3) data are readily available through multitude of sources; and (4) ascertainment is not subject to interrater variabil…”
BackgroundMethodAwad, I. A., Polster, S. P., Carrión‐Penagos, J., Thompson, R. E., Cao, Y. J., Stadnik, A., Money, P. L., Fam, M. D., Koskimäki, J., Girard, R., et al. (2019) · Neurosurgery · doi:10.1093/neuros/nyz077 · Cited by 155
“Surgeon fully qualified 59 (24) 39 (66) 17 (29) 3 (5) 0.”
Self-citationFunctional outcome after convulsive status epilepticus
Legriel, S., Azoulay, É., Resche‐Rigon, M., Lemiale, V., Mourvillier, B., Kouatchet, A., Troché, G., Wolf, M., Galliot, R., Dessertaine, G., et al. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181f859a6 · Cited by 152
“However, 90 days is the most widely used interval for assessing overall outcomes after brain injuries (14, 17, 18).”
BackgroundTime Course and Predictors of Neurological Deterioration After Intracerebral Hemorrhage
Lord, A. S., Gilmore, E. J., Choi, H., & Mayer, S. A. (2015) · Stroke · doi:10.1161/strokeaha.114.007704 · Cited by 148
Self-citationMeretoja, A., Yassi, N., Wu, T. Y., Churilov, L. P., Sibolt, G., Jeng, J., Kleinig, T. J., Spratt, N. J., Thijs, V., Wijeratne, T., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30369-0 · Cited by 157
Self-citationSafety and Tolerability of Deferoxamine Mesylate in Patients With Acute Intracerebral Hemorrhage
Selim, M. H., Yeatts, S. D., Goldstein, J. N., Gomes, J. A., Greenberg, S. M., Morgenstern, L. B., Schlaug, G., Torbey, M., Waldman, B. D., Xi, G., et al. (2011) · Stroke · doi:10.1161/strokeaha.111.617589 · Cited by 149
Stroke Prevention and Treatment
Marsh, J. D., & Keyrouz, S. G. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.072 · Cited by 165
Hematoma volume as the major determinant of outcomes after intracerebral hemorrhage
LoPresti, M. A., Bruce, S. S., Camacho, E., Kunchala, S., DuBois, B. G., Bruce, E. M., Appelboom, G., & Connolly, E. S. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.06.057 · Cited by 158
“However, other studies have shown that while hematoma expansion is greatest acutely, growth can be seen more than 6 h after onset, while no growth was observed between 24 and 48 h after onset [48].”
BackgroundInfluentialReversal agents for non-vitamin K antagonist oral anticoagulants
Levy, J. H., Douketis, J. D., & Weitz, J. I. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.223 · Cited by 154
Ziai, W., & Carhuapoma, J. R. (2018) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000672 · Cited by 170
Delcourt, C., Huang, Y., Wang, J., Heeley, E., Lindley, R., Stapf, C., Tzourio, C., Arima, H., Parsons, M., Sun, J., et al. (2010) · International Journal of Stroke · doi:10.1111/j.1747-4949.2010.00415.x · Cited by 140
Metadata
- Authors
- Mayer, S. A., Brun, N. C., Begtrup, K., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., & Steiner, T.
- Affiliations
- Columbia University Irving Medical Center (US)
- Novo Nordisk (Denmark) (DK)
- University of Cincinnati Medical Center (US)
- The Royal Melbourne Hospital (AU)
- Washington University in St. Louis (US)
- Heidelberg University (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-15
- Volume
- 358
- Issue
- 20
- Pages
- 2127-2137
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2142640478
- Cited by
- 1,255
- References
- 29
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 44 · 2023: 36 · 2022: 38 · 2021: 75 · 2020: 71 · 2019: 57 · 2018: 59 · 2017: 75 · 2016: 60 · 2015: 68 · 2014: 77 · 2013: 90 · 2012: 105
- FWCI
- 70.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Health Sciences › Medicine › Clinical Neurology › Intracranial Aneurysms: Treatment and Complications
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- recombinant factor VIIa, intracerebral hemorrhage, hematoma expansion, hemorrhagic stroke, thromboembolic adverse events, functional outcome, modified Rankin Scale, hemostatic therapy, dose comparison, arterial events, bleeding complications, arterial thrombosis, venous thromboembolism
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cerebral Hemorrhage, Double-Blind Method, Female, Hematoma, Humans, Male, Middle Aged, Recombinant Proteins, Tomography, X-Ray Computed, Glasgow Coma Scale, Factor VIIa, Treatment Failure, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.